Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities

Area of Science:

• Pharmaceutical Chemistry
• Analytical Chemistry
• Toxicology

Background:

• N-nitrosamine impurities in pharmaceuticals pose a significant quality management challenge due to their potent carcinogenicity.
• Regulatory actions, including drug recalls, highlight the urgent need to assess and control N-nitrosamine contamination.
• Establishing acceptable intake (AI) levels is crucial for risk assessment and guiding analytical testing strategies.

Purpose of the Study:

• To derive acceptable intake (AI) levels for complex N-nitrosamine impurities lacking carcinogenicity data.
• To facilitate the development of analytical methods for detecting these unique pharmaceutical impurities.
• To support regulatory compliance and ensure the safety of medicinal products.

Main Methods:

• Cataloging and grouping complex N-nitrosamine impurities based on shared structural features (13 groups defined).
• Reviewing carcinogenicity data of structurally related N-nitrosamines to inform group AI derivation.
• Conservatively deriving group AIs based on the most potent N-nitrosamine within each structural category.

Main Results:

• Acceptable intake (AI) levels were successfully derived for numerous complex N-nitrosamine impurities.
• The derived AIs for several N-nitrosamine groups were significantly higher than those for simple N,N-dialkylnitrosamines.
• Higher AIs enable commensurately higher analytical method detection limits, simplifying impurity analysis.

Conclusions:

• The study provides a framework for establishing AIs for complex N-nitrosamines, addressing a critical gap in pharmaceutical safety.
• The derived AIs are essential for setting appropriate analytical specifications and managing risks associated with these impurities.
• This work aids in the quality control of pharmaceuticals by enabling more practical and effective analytical testing for N-nitrosamine contaminants.